October 9, 2024 05:32 AM EDTUpdated 06:43 AM
Deals

Kevin Tang's Con­cen­tra swoops in on an­oth­er strug­gling biotech, of­fer­ing to buy Kezar

Kyle LaHucik

Senior Reporter

Con­cen­tra Bio­sciences, a shell com­pa­ny from Tang Cap­i­tal, wants to buy an­oth­er biotech that has found it­self in a bind.

Kevin Tang’s shop told Kezar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

David Bak­er, Demis Has­s­abis and John Jumper win chem­istry No­bel for com­pu­ta­tion­al pro­tein pre­dic­tion and de­sign

Pure­spring nabs $105M to take gene ther­a­py in­to the clin­ic as IgAN field ma­tures

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Base­camp rais­es $60M to trav­el the globe and fill AI da­ta gaps, signs deal with David Liu

No­bel Prize win­ner Demis Has­s­abis talks about his vi­sion for Iso­mor­phic and AI’s fu­ture in biotech

Pfiz­er culls RSV treat­ment from Re­Vi­ral ac­qui­si­tion

A service from the Financial Times